Jul. 12 at 3:50 PM
FY2026 revenue multiples for all 29 comm'l-stage (or almost comm'l-stage) oncology (MCs
$200MM+) & all 55 non-oncology (MC's
$600MM+) focused bios.
$IOVA trades at the lowest FY26 revenue multiple (excl those with recent bad news like SRPT). A data read in certain lung cancers is imminent. If the data is compelling then the TIL TAM would dramatically increase.
We'd guess near-term M&A candidates include:
$JAZZ (JAZZ's EV is ~
$3B more than market cap...multiples are based on market cap).
$TARS
$TGTX
$AGIO
We track these data points manually so we could have made a mistake. Otherwise, this is just for fun for entertainment purposes only. We have no idea who is most likely to be acquired.
